Sorrento Therapeutics (SRNE +6.9%) perks up on below-average volume in reaction to its statement that it has chosen a COVID-19 vaccine candidate, dubbed T-VIVA-19, to advance into the clinic and, if successful, into the marketplace.
It says T-VIVA-19 is a recombinant fusion protein of the spike protein S1 domain and the Fc portion of the human IgG1 antibody.
The company also says its existing bulk drug substance manufacturing capacity should enable it to make up to 100M doses per month.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.